A research study investigating magic mushrooms in Canada revealed that nearly 80% of participants advocated for psilocybin, a compound found in magic mushrooms, to be available as a medical treatment for distressed patients. Moreover, approximately two-thirds of the Canadian participants in the same study supported the idea of making psilocybin legally accessible for those in need.
Besides advocating for increased availability, a significant 84.8 percent of participants expressed their belief that the public health system should cover the costs of such therapies. The majority of Canadians consider psilocybin as a credible treatment option, especially for end-of-life distress.
[toc]
Key Takeaways:
- Residents of Québec, Ontario, Alberta, and British Columbia view psilocybin as a legitimate medical choice to manage end-of-life existential distress.
- Magic mushrooms are perceived as safe for treating existential distress.
- Participants in two double-blind trials reported immediate and long-lasting benefits, with effects persisting for six months or longer.
Understanding Existential Distress
Existential distress, akin to existential suffering, spiritual distress, and demoralization, arises when individuals confront their mortality. Patients may grapple with feelings of helplessness, isolation, anxiety, and a loss of meaning and purpose. This kind of distress particularly impacts patients with life-threatening illnesses, potentially leading to suicidal thoughts or a desire for hastened death.
Usually, individuals facing terminal illnesses or significant life changes are the ones who typically experience this kind of distress. It significantly impairs their mental health and overall quality of life.
Existential therapy aims to address issues such as anxiety, depression, grief, loneliness, apathy, despair, identity confusion, and feelings of purposelessness and existential fear. It often necessitates multiple sessions and may not be effective for everyone.
The uncertainty regarding the effectiveness of such therapy is a main reason why many individuals seek alternative treatments.
Health Canada’s Stance on Psilocybin as a Therapeutic Option
Over the past two decades, preliminary clinical trials have highlighted the possible advantages of using psychedelic substances to treat complex mental disorders. Specifically, psilocybin has demonstrated quick and long-lasting relief from existential distress in patients nearing the end of their lives.
Recognizing the potential effectiveness of these proposed hallucinogenic mushrooms, especially when conventional treatments do not suffice, Health Canada updated the Special Access Program in 2022. This enables healthcare professionals to request controlled substances for their patients.
Canadian Advocacy for Psilocybin Access
A research study presented in the Palliative Care Journal evaluates societal views on psilocybin-assisted therapy for end-of-life care. The data from the study includes:
| Methodology | Input from 2,800 Canadians from Québec, Ontario, Alberta, and British Columbia. Of these, 19% had previously used psilocybin (15% in Québec, 26% in British Columbia). |
| Findings | 79.3% regard psilocybin-assisted therapy as a legitimate medical option for treating end-of-life existential distress. 63.3% think psilocybin should be integrated into medical treatment. 84.8% endorse the delivery of this therapy by the public health system. 44.2% believe healthcare professionals should administer the substance without Health Canada’s supervision. |
These outcomes align with surveys conducted in Canada, England, and Australia. The researchers underscored the uniqueness of their study as it focuses on the use of psychoactive substances to alleviate existential distress in end-of-life situations.
Why Canadians Support Psilocybin Use
An increasing number of Canadians are supporting the use of psilocybin for treatment, largely influenced by findings from esteemed research institutions. Another major factor is the perceived safety of psilocybin mushrooms for mitigating existential distress. No severe harmful health effects, such as multi-organ failure, have been reported by subjects across various studies.
| Study | Approach | Outcomes |
| Johns Hopkins Study | 51 patients were administered a high dose of psilocybin and a low dose as an active placebo control | Immediate and prolonged |
| The therapy’s effectiveness is largely due to profound emotional insights and mystical experiences that foster a sense of unity. These benefits can last up to six months, or even longer. | ||
| Trial at New York University | 29 patients were randomly selected to receive either psilocybin or the active placebo, niacin | The results of the study were consistent with the findings of the Johns Hopkins study. Participants who received psilocybin reported psychological relief and a more positive outlook on life and death. |
| BMC Palliative Care | The study aimed to understand the perception of existential distress by palliative care professionals and their views on psychedelic therapy as a treatment option. Nineteen participants were interviewed, including 7 doctors, 4 active nurses, 4 chaplains, 3 social workers, and a psychologist. | Psychedelic-Assisted Therapy (PAT) shows promise in alleviating existential distress, as per the palliative care practitioners. |
Patient Experiences
Besides scientific studies, numerous patient narratives highlight psilocybin’s effectiveness in improving mental wellbeing and life quality.
Journey of Yokoi
Mio Yokoi, a terminal stage 4 pancreatic cancer patient, shares her transformative experience during her assisted therapy. She envisions herself on a raft in nature, accompanied by whimsical creatures. This vision evokes a deep understanding of the universe’s interconnectedness and support, fostering immense peace and affirmation in her.
Despite availing traditional mental health support, Yokoi still faced severe anxiety and distress following her diagnosis. Psilocybin therapy helped her reconnect with her body and offered a tangible sense of love and support. This vastly improved her emotional and mental health.
Story of Chrissy
Chrissy, a woman in her 50s, was diagnosed with stage 4 breast cancer that had metastasized to her lungs. She was working full-time as an administrative supervisor in healthcare during the study and identified herself as an atheist. She was diagnosed with Generalized Anxiety Disorder during her screening.
Chrissy experienced significant decreases in her anxiety, depression, fear of death, hopelessness, and demoralization levels. When asked about any changes in her religious or spiritual beliefs post-therapy, she stated that the experiences had added substance and authenticity to her beliefs.
Brenda’s Journey
In her therapy sessions, Brenda reported experiencing death twice. However, these experiences led her to view death not as a fear, but as a beautiful part of life’s cycle. She credited the study as the catalyst for her journey of healing from past childhood trauma. The data collected from her sessions reflected this profound transformation.
Her anxiety and fear of death significantly diminished, and she experienced a notable increase in her sense of spirituality.
Availability of Psilocybin Products in Canada
Presently, access to psilocybin capsules and related products, intended for the management of existential distress and other mental health concerns, may be limited. However, reliable online dispensaries can be a good source for these products when needed.
| Product Attributes | Brazilian Psilocybe Cubensis | Cambodian Psilocybe Cubensis | Melmac Psilocybe Cubensis |
| Source | Originates from Brazil and other South American countries nearby. | Sourced from Cambodia, particularly around the Angkor Wat Temple. | Related to the Penis Envy mushrooms, which became popular in the 1970s. |
| Strength | Of medium strength; suitable for beginners. | Also of medium strength; ideal for those new to its use. | Highly potent; advisable for those with a moderate to advanced level of experience. |
| Effects | Leads to a mental stimulation, slight confusion, enhanced color perception, euphoria, spiritual insights, increased creativity, and improved concentration. | Induces an energizing and enduring high, minor visual changes, increased creativity, euphoria, a gentle physical high, fractal images, and feelings of joy. | Produces profound shamanic experiences, vision quests, intense mystical experiences, heightened creativity, focus, social awareness, and mood improvement. |
Mitigate End-of-life Discomfort with Psilocybin Products
Existential anxiety or distress as one nears the end of life can significantly affect many patients’ well-being. With traditional treatments occasionally falling short, there is a growing movement in Canada to allow easier access to magic mushrooms within the public healthcare system. This increasing public interest could
We urge regulatory authorities to explore the potential of magic mushrooms as a valid treatment option. Obtain your psychedelics and shroom delivery from Magic Mushrooms Winnipeg Canada.
Frequently Asked Questions
What should patients expect from Psilocybin-Assisted Therapy?
The experiences of patients participating in Psychedelic-assisted therapy (PAT) can greatly differ. For a positive outcome, it’s crucial to prepare adequately and adhere to specific procedures. Patients are required to undergo extensive screening and mental readiness before taking the substance.
- Preparation before the Session: The patients are thoroughly evaluated. The therapist discusses the patient’s goals and expectations to set the session’s intentions. The therapist also explains the process’s impact and what the patient can expect during the session.
- The Session: A controlled dose of the substance is administered to the patients during the session. The session occurs in a tranquil, distraction-free environment conducive to relaxation and introspection. The therapist provides ongoing support and direction throughout this process.
- Post-Session Integration Therapy: This therapy helps patients comprehend and process their experiences. Follow-up sessions provide ongoing support and counselling to reinforce the insights and changes achieved during the therapy.
How does psilocybin affect the brains of distressed patients?
Psilocybin interacts with the brain by attaching to serotonin receptors, primarily the 5-HT2A receptor. This interaction can trigger changes in perception, mood, and cognition, causing significant shifts in consciousness, emotional breakthroughs, and new perspectives.
Is psilocybin therapy available to everyone?
Psilocybin therapy is not suitable for everyone. Patients with certain mental health conditions or existential distress are thoroughly screened to eliminate those with a history of psychosis.
Related Articles:
